Filing Details
- Accession Number:
- 0001477932-18-000851
- Form Type:
- 13G Filing
- Publication Date:
- 2018-02-14 15:07:25
- Filed By:
- Skidmore Brian
- Company:
- Immune Pharmaceuticals Inc (NASDAQ:IMNPQ)
- Filing Date:
- 2018-02-14
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Brian Skidmore | 13,525 | 900,148 | 13,525 | 900,148 | 913,673 | 4.4% |
| Melanie Skidmore | 19,925 | 900,148 | 19,925 | 900,148 | 920,073 | 4.4% |
| Bri-Mel Holdings Ltd | 726,192 | 0 | 726,192 | 0 | 726,192 | 3.5% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
| Immune Pharmaceuticals Inc. |
| (Name of Issuer) |
Common Stock
(Title of Class of Securities)
45254C200
(CUSIP Number)
December 31, 2017
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 45254C200 |
|
| 1 | NAMES OF REPORTING PERSONS
Brian Skidmore | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) x
(b) ¨ | ||
| 3 | SEC USE ONLY
| ||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Canada | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
13,525 | |
| 6 | SHARED VOTING POWER
900,148 | ||
| 7 | SOLE DISPOSITIVE POWER
13,525 | ||
| 8 | SHARED DISPOSITIVE POWER
900,148 | ||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
913,673 | ||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
| ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.4%* | ||
| 12 | TYPE OF REPORTING PERSON (See Instructions)
IN | ||
____________
* Percentage was calculated based on a total of 21,000,999 shares outstanding on December 31, 2017.
| 2 |
| CUSIP No. 45254C200 |
|
| 1 | NAMES OF REPORTING PERSONS
Melanie Skidmore | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) x
(b) ¨ | ||
| 3 | SEC USE ONLY
| ||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
Canada | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
19,925 | |
| 6 | SHARED VOTING POWER
900,148 | ||
| 7 | SOLE DISPOSITIVE POWER
19,925 | ||
| 8 | SHARED DISPOSITIVE POWER
900,148 | ||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
920,073 | ||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
| ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.4%* | ||
| 12 | TYPE OF REPORTING PERSON (See Instructions)
IN | ||
____________
* Percentage was calculated based on a total of 21,000,999 shares outstanding on December 31, 2017.
| 3 |
| CUSIP No. 45254C200 |
|
| 1 | NAMES OF REPORTING PERSONS
Bri-Mel Holdings Ltd. | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) x
(b) ¨ | ||
| 3 | SEC USE ONLY
| ||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION
British Columbia | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER
726,192 | |
| 6 | SHARED VOTING POWER
0 | ||
| 7 | SOLE DISPOSITIVE POWER
726,192 | ||
| 8 | SHARED DISPOSITIVE POWER
0 | ||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
726,192 | ||
| 10 | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) ¨
| ||
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.5%* | ||
| 12 | TYPE OF REPORTING PERSON (See Instructions)
CO | ||
* Percentage was calculated based on a total of 21,000,999 shares outstanding on December 31, 2017.
| 4 |
Item 1.
| (a) | Name of issuer: |
|
|
|
|
| Immune Pharmaceuticals Inc. |
| (b) | Address of issuer’s principal executive offices: |
|
|
|
|
| 550 Sylvan Avenue, Englewood Cliffs, NJ 07632 |
Item 2.
| (a) – (c) | Name, address and citizenship of each reporting person:
Brian Skidmore PO Box 370 Milner, BC V0X 1T0 Canada Citizenship: Canada
Melanie Skidmore PO Box 370 Milner, BC V0X 1T0 Canada Citizenship: Canada
Bri-Mel Holdings Ltd. PO Box 370 Milner, BC V0X 1T0 Canada Citizenship: Organized under the laws of British Columbia |
| (d) | Title of class of securities: |
|
|
|
|
| Common Stock |
| (e) | CUSIP No.: |
|
|
|
|
| 45254C200 |
Item 3.
Not applicable.
| 5 |
Item 4. Ownership.
The following information regarding beneficial ownership of the common stock of the issuer is given as of December 31, 2017, with percentages being based on a total of 21,000,999 shares of common stock outstanding as of December 31, 2017.
| (a) | Amount beneficially owned: |
|
|
|
|
| Brian Skidmore beneficially owns 913,673 shares.
Melanie Skidmore beneficially owns 920,073 shares.
Bri-Mel Holdings Ltd. beneficially owns 726,192 shares.
Collectively as a group, the reporting persons beneficially own 933,598 shares. |
| (b) | Percent of class: |
|
|
|
|
| Brian Skidmore beneficially owns 4.4% of the class of shares.
Melanie Skidmore beneficially owns 4.4% of the class of shares.
Bri-Mel Holdings Ltd. beneficially owns 3.5% of the class of shares.
Collectively as a group, the reporting persons beneficially own 4.4% of the class of shares. |
| (c) | Number of shares as to which the persons have: |
|
| (i) | Sole power to vote or to direct the vote: |
|
|
|
|
|
|
| Brian Skidmore has sole power to vote or direct the vote of 13,525 shares.
Melanie Skidmore has sole power to vote or direct the vote of 19,925 shares.
Bri-Mel Holdings Ltd. has sole power to vote or direct the vote of 726,192 shares. |
|
| (ii) | Shared power to vote or to direct the vote: |
|
|
|
|
|
|
| Brian Skidmore and Melanie Skidmore have shared power to vote or direct the vote of 900,148 shares.
Bri-Mel Holdings does not have shared power to vote any shares. |
|
| (iii) | Sole power to dispose or to direct the disposition of: |
|
|
|
|
|
|
| Brian Skidmore has sole power to dispose or direct the disposition of 13,525 shares.
Melanie Skidmore has sole power to dispose or direct the disposition of 19,925 shares.
Bri-Mel Holdings Ltd. has sole power to dispose or direct the disposition of 726,192 shares. |
| 6 |
|
| (iv) | Shared power to dispose or to direct the disposition of: |
|
|
|
|
|
|
| Brian Skidmore and Melanie Skidmore have shared power to dispose or to direct the disposition of 900,148 shares. |
|
|
|
|
|
|
| Bri-Mel Holdings does not have shared power to dispose or direct the disposition of any shares. |
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not applicable.
Item 8. Identification and Classification of Members of the Group.
See Exhibit “B”.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certifications.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
| 7 |
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 14, 2018
| /s/ Brian Skidmore | |||
|
|
| Brian Skidmore | |
|
|
| /s/ Melanie Skidmore |
|
|
|
| Melanie Skidmore |
|
|
|
| Bri-Mel Holdings Ltd. |
|
|
|
|
|
|
|
| By: | /s/ Brian Skidmore |
|
|
|
| Brian Skidmore, President |
|
| 8 |
EXHIBIT “A”
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each them of a statement on Schedule 13G (including amendments thereto) with respect to the shares of common stock of Immune Pharmaceuticals Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as Exhibit “A” to such Schedule 13G. In evidence thereof, the undersigned hereby execute this agreement this 28th day of June, 2017.
| /s/ Brian Skidmore | |||
|
|
| Brian Skidmore | |
| /s/ Melanie Skidmore | |||
|
|
| Melanie Skidmore |
|
|
|
|
|
|
|
|
| Bri-Mel Holdings Ltd. |
|
|
|
|
|
|
|
| By: | /s/ Brian Skidmore |
|
|
|
| Brian Skidmore, President |
|
| 9 |
EXHIBIT “B”
Brian Skidmore
Melanie Skidmore
Bri-Mel Holdings Ltd.
| 10 |